Specific protein delivery to target cells by antibody-displaying bionanocapsules

Journal of Biochemistry

Volumn 144, Issue 6, 2008, Pages 701-707

  Kurata, Naoya ^a   Shishido, Takuya ^a   Muraoka, Masaru ^a   Tanaka, Tsutomu ^a   Ogino, Chiaki ^a   Fukuda, Hideki ^a   Kondo, Akihiko ^a  

^a KOBE UNIVERSITY   (Japan)

Author keywords

Antibody mediated targeting; Bionanocapsule; Insect cell expression system; Protein delivery; ZZ domain

Indexed keywords

ANTIBODY; ENHANCED GREEN FLUORESCENT PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; NANOCAPSULE; PROTEIN A;

ARTICLE; BIOENGINEERING; CELL SPECIFICITY; GENE EXPRESSION SYSTEM; HELA CELL; HUMAN; HUMAN CELL; INSECT CELL; PROTEIN DOMAIN; PROTEIN TARGETING; PROTEIN TRANSPORT; SURFACE PROPERTY; TARGET CELL;

ANTIBODIES; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HELA CELLS; HUMANS; NANOPARTICLES; PROTEIN ENGINEERING; PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

HEPATITIS B VIRUS; HEXAPODA;

EID: 57749173811     PISSN: 0021924X     EISSN: 17562651     Source Type: Journal    
DOI: 10.1093/jb/mvn131     Document Type: Article

References (33)

1. Foerg, C. and Merkle, H.P. (2007) On the biomedical promise of cell penetrating peptide. J. Pharm. Sci. 97, 144-162
2. Hansen, J.E., Fischer, L.K., Chan, G., Chang, S.S., Baldwin, S.W., Aragon, R.J., Carter, J.J., Lilly, M., Nishimura, R.N., Weisbart, R.H., and Reeves, M.E. (2007) Antibody-mediated p53 protein therapy prevents liver metastasis in vivo. Cancer. Res. 67, 1769-1774
3. Senatus, P.B., Li, Y., Mandigo, C., Nichols, G., Moise, G., Mao, Y., Brown, M.D., Anderson, R.C., Parsa, A.T., Brandt-Rauf, P.W., Bruce, J.N., and Fine, R.L. (2006) Restoration pf p53 function for selective Fas-mediated apoptosis in human and rat glioma cells in vitro and in vivo by a p53 COOH-terminal peptide. Mol. Cancer Ther. 5, 20-28
4. Harada, H., Kizaka-Kondoh, S., and Hiraoka, M. (2006) Antitumor protein therapy; application of the protein transduction domain to the development of a protein drug for cancer treatment. Breast Cancer 13, 16-26
5. Spagnou, S., Miller, A.D., and Keller, M. (2004) Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA. Biochemistry 43, 13348-13356
6. Rawat, M., Singh, D., Saraf, S., and Saraf, S. (2006) Nanocarriers: promising vehicle for bioactive drug. Biol. Pharm. Bull. 29, 1790-1798
7. Sethuraman, V.A., Na, K., and Bae, Y.H. (2006) pH-responsive sulfonamide/PEI system for tumor specific gene delivery: an in vitro study. Biomacromolecules 7, 64-70
8. Boado, R.J. (2007) Blood-brain barrier transport of non-viral gene and RNAi therapeutics. Pharm. Res. 24, 1772-1787
9. Kuroda, S., Otaka, S., Miyazaki, T., Nakao, M., and Fujisawa, Y. (1992) Hepatitis B virus envelope L protein particles. Synthesis and assembly in Saccharomyces cerevisiae, purification and characterization. J. Biol. Chem. 267, 1953-1961
10. Yamada, T., Iwasaki, Y., Tada, H., Iwabuki, H., Chuah, M.K., VandenDriessche, T., Fukuda, H., Kondo, A., Ueda, M., Seno, M., Tanizawa, K., and Kuroda, S. (2003) Nanoparticles for the delivery of genes and drugs to human hepatocytes. Nat. Biotechnol. 21, 885-890
11. Paran, N., Geiger, B., and Shaul, Y. (2001) HBV infection of cell culture: evidence for multivalent and cooperative attachment. EMBO J. 20, 4443-4453
12. Glebe, D., Aliakbari, M., Krass, P., Knoop, E.V., Valerius, K.P., and Gerlich, W.H. (2003) Pre-s1 antigen-dependent infection of Tupaia hepatocyte cultures with human hepatitis B virus. J. Virol. 77, 9511-9521
13. Jendeberg, L., Persson, B., Anderssonm, R., Karlsson, R., Uhlén, M., and Nilsson, B. (1995) Kinetic analysis of the interaction between protein A domain variants and human Fc plasmon resonance detection. J. Mol. Recognit. 8, 270-278
14. Nilsson, B., Moks, T., Jansson, B., Abrahmsén, L., Elmblad, A., Holmgren, E., Henrichson, C., Jones, T.A., and Uhlén, M. (1987) A synthetic IgG-binding domain based on staphylococcal protein A. Protein. Eng. 1, 107-113
15. Tsutsui, Y., Tomizawa, K., Nagita, M., Michiue, H., Nishiki, T., Ohmori, I., Seno, M., and Matsui, H. (2007) Development ob bionanocapsules targeting brain tumors. J. Control. Release 122, 159-164
16. Jung, J., Matsuzaki, T., Tatematsu, K., Okajima, T., Tanizawa, K., and Kuroda, S. (2008) Bio-nanocapsule conjugated with liposomes for in vivo pinpoint delivery of various materials. J. Control. Release 126, 255-264
17. Shimojyo, R., Furukawa, H., Fukuda, H., and Kondo, A. (2003) Preparation of yeast strains displaying IgG binding domain ZZ and enhanced green fluorescent protein for novel antigen detection system. J. Biosci. Bioeng. 96, 493-495
18. Shishido, T., Kurata, N., Myung, Y., Tanaka, T., Yamaji, H., Fukuda, H., and Kondo, A. High-level expression vector containing selectable marker for continuous production of recombinant protein in insect cells. Submitted.
19. Yu, D., Amano, C., Fukuda, T., Yamada, T., Kuroda, S., Tanizawa, K., Kondo, A., Ueda, M., Yamada, H., Tada, H., and Seno, M. (2005) The specific delivery of proteins to human liver cells by engineered bio-nanocapsules. FEBS J. 272, 3651-3660
20. Shishido, T., Muraoka, M., Ueda, M., Seno, M., Tanizawa, K., Kuroda, S., Fukuda, H., and Kondo, A. (2006) Secretory production system of bionanocapsules using a stably transfected insect cell line. Appl. Microbiol. Biotechnol. 73, 505-511
21. Heermann, K.H., Goldmann, U., Schwartz, W., Seyffarth, T., Baumgarten, H., and Gerlich, W.H. (1984) Large surface proteins of hepatitis B virus containing the pre-s sequence. J. Virol. 52, 396-402
22. Yamada, T., Iwabuki, H., Kannno, T., Tanaka, H., Kawai, T., Fukuda, H., Kondo, A., Seno, M., Tanizawa, K., and Kuroda, S. (2001) Physicochemical and immunological characterization of hepatitis B virus envelope particles exclusively consisting of the entire L (pre-S1 + pre-S2 + S) protein. Vaccine 19, 3154-3163
23. Berkers, J.A., van Bergen en Henegouwen, P.M., and Boonstra, J. (1991) Three classes of epidermal growth factor receptors on HeLa cells. J. Biol. Chem. 266, 922-927
24. Yarden, Y. (2001) The EGFR family and its ligands in human cancer. Signaling mechanisms and therapeutic opportunities. Eur. J. Cancer 37, S3-S8
25. Sato, J.D., Kawamoto, T., Le, A.D., Mendelsohn, J., Polikoff, J., and Sato, G.H. (1983) Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol. Biol. Med. 1, 511-529
26. Schreiber, A.B., Libermann, T.A., Lax, I., Yarden, Y., and Schlessinger, J. (1983) Biological role of epidermal growth factor-receptor clustering. Investigation with monoclonal anti-receptor antibodies. J. Biol. Chem. 258, 846-853
27. Mamot, C., Drummond, D.C., Greiser, U., Hong, K., Kirpotin, D.B., Marks, J.D., and Park, J.W. (2003) Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer Res. 63, 3154-3161
28. Mamot, C., Ritschard, R., Küng, W., Park, J.W., Heerrmann, R., and Rochlitz, C.F. (2006) EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells. J. Drug Target. 14, 215-223
29. Pan, X., Wu, G., Yang, W., Barth, R.F., Tjarks, W., and Lee, R.J. (2007) Synthesis of cetuximab-immunoliposomes via a cholesterol-based membrane anchor for targeting of EGFR. Bioconjug. Chem. 18, 101-108
30. Pan, X. and Lee, R.J. (2007) Construction of anti-EGFR immunoliposomes via folate-folate binding protein affinity. Int. J. Pharm. 336, 276-283
31. Kim, M.J., Lee, H.J., Lee, I.A., Kim, I.Y., Lim, S.K., Cho, H.A., and Kim, J.S. (2008) Preparation of pH-sensitive, long-circulating and EGFR-targeted immunoliposomes. Arch. Pharm. Res. 31, 539-546
32. Wiley, H.S. (2003) Trafficking of the ErbB receptors and its influence on signaling. Exp. Cell. Res. 284, 78-88
33. Stoeckl, L., Funk, A., Kopitzki, A., Brandenburg, B., Oess, S., Will, H., Sirma, H., and Hildt, E. (2006) Identification of a structural motif crucial for infectivity of hepatitis B viruses. Proc. Natl Acad. Sci. USA 103, 6730-6734